Epizyme Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Epizyme (EPZM) 6M Offering Prices at $20.75/Share
March 18, 2015 8:16 AM EDTEpizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 6,000,000 shares of its common stock at a price of $20.75 per share before underwriting discounts. All of the shares of common stock to be sold in the offering are to be sold by Epizyme. In addition, Epizyme... More
Epizyme (EPZM) to Offer 4.75M Common Shares
March 16, 2015 4:19 PM EDTEpizyme (NASDAQ: EPZM) announced that it intends to offer and sell up to 4,750,000 shares of its common stock in an underwritten public offering. Epizyme intends to grant the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock. All of the shares of... More
